Effect of Prophylactic Ketorolac on CME After Cataract Surgery

Queen's University

Status: Completed

Conditions: Macular Edema, Cystoid

Treatments: Drug: ketorolac tromethamine 0.5% (Acular®)

Study type: Interventional

Funder types: Other

Identifiers

NCT00335439

QUEENS-SRE-2

Details and patient eligibility

About

The study will evaluate the efficacy of prophylactic administration of the topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac tromethamine 0.5% (Acular®) on cystoid macular edema (CME) in patients having undergone cataract surgery. CME is the most frequent cause of decreased vision after uncomplicated cataract surgery and can result in irreversible sight reduction. The investigation will involve a comparison arm and a treatment arm with both sets of patient populations being evaluated for CME with ophthalmologic examinations and optical coherence tomography (OCT) measurements. The objective is to elucidate the role of NSAID drops in preventing CME after cataract surgery.

Enrollment: 98 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• First cataract surgery (i.e., first eye).

Exclusion criteria

• hypersensitivity to the NSAID drug class,
• pregnancy.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)